Select a main research category to review its subcategories and current study summaries. Study availability and enrollment status can change. A research coordinator will confirm whether a study is currently available and explain the screening process.
Oncology
Breast cancer
ELECTRA: A Phase 1b/2 study evaluating elacestrant with abemaciclib for ER-positive, HER2-negative breast cancer with brain metastases.
Lasofoxifene and abemaciclib: A randomized study comparing lasofoxifene plus abemaciclib with fulvestrant plus abemaciclib for advanced ER-positive, HER2-negative breast cancer with an ESR1 mutation.
Advanced solid tumors
ASP1570: A Phase 1 study evaluating ASP1570 in participants with advanced solid tumors across eligible tumor types.
ONM-501: A Phase 1 dose-escalation and expansion study of intratumoral ONM-501 alone or with cemiplimab in advanced solid tumors and lymphomas.
AMG 193: A Phase 1/1b/2 study of AMG 193 alone or with docetaxel in advanced MTAP-null solid tumors, including selected NSCLC, gastrointestinal, and glioma cohorts.
DB-1303: A first-in-human Phase 1/2a study assessing safety, tolerability, pharmacokinetics, and preliminary antitumor activity in advanced or metastatic solid tumors.
DB-1305: A first-in-human Phase 1/2a study in advanced or metastatic solid tumors, with selected cohorts including lung, mesothelioma, cervical, head and neck, ovarian, and breast cancers.
INBRX-106: A Phase 1/2 study evaluating INBRX-106 alone and with pembrolizumab in locally advanced or metastatic solid tumors, including an NSCLC cohort.
Prostate cancer
ZEN003694: A randomized Phase 2b study of ZEN003694 with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer.
Non-small cell lung cancer
EIK1001: A Phase 2 study of EIK1001 with pembrolizumab and chemotherapy for Stage IV non-small cell lung cancer.
NSCLC pneumonitis observational study: A prospective study of people receiving standard-of-care NSCLC treatment associated with a risk of pneumonitis or interstitial lung disease.
Valemetostat and pembrolizumab: A Phase 1b/2 trial comparing valemetostat plus pembrolizumab with pembrolizumab alone in previously untreated, advanced PD-L1-high NSCLC without actionable genomic alterations.
Head and neck cancer
BNT113: A Phase 2 study comparing BNT113 plus pembrolizumab with pembrolizumab alone in HPV16-positive, PD-L1-expressing recurrent or metastatic head and neck squamous cell carcinoma.
TRK fusion cancer
ON-TRK: A prospective observational study of people with locally advanced or metastatic TRK fusion cancer treated with larotrectinib.
Rheumatology
Obexelimab: A randomized, double-blind Phase 2 study evaluating the efficacy and safety of obexelimab in systemic lupus erythematosus.
BIIB059: A Phase 3 study evaluating BIIB059 in adults with active systemic lupus erythematosus receiving background nonbiologic standard-of-care therapy.
Baricitinib: A pragmatic Phase 3b/4 study evaluating baricitinib in people with rheumatoid arthritis.
Thyroid eye disease
IMVT-1401-3201: A Phase 3 randomized, quadruple-masked, placebo-controlled study of batoclimab for active thyroid eye disease.
Pediatrics and adolescent health
Ferric derisomaltose: A Phase 3 study in children with iron-deficiency anemia related to non-dialysis chronic kidney disease or intolerance or inadequate response to oral iron.
LF111 or drospirenone: A controlled study examining bone mineral density in adolescent and adult women using selected contraceptive tablets compared with nonusers of hormonal contraception.
Pulmonology
MIRANDA: A Phase 3 randomized, double-blind study evaluating tozorakimab in symptomatic COPD with a history of exacerbations.
Request study information
Complete this form and a research coordinator will follow up. Do not submit medical records, diagnoses, insurance details, or other sensitive health information.